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OBJECTIVEdGenetic variants near IRS1 are associated with features of the metabolic syn-
drome (MetS). We examined whether genetic variants near IRS1 might modulate the effects of
diets varying in fat content on the MetS status in a 2-year weight-loss trial.
RESEARCH DESIGN AND METHODSdTwo variants near IRS1, rs1522813 and
rs2943641, were genotyped in 738 overweight/obese adults (age 60 6 9 years; BMI 32.7 6
3.9 kg/m
2)randomly assignedto one of four weight-lossdiets (a deﬁcitof750kcal/dayofcaloric
intakefrombaseline)varyinginmacronutrient contentsfor 2years.WecomparedMetSstatusof
high-fat (40% of caloric intake; n = 370) and low-fat (20% caloric intake; n = 368) diet groups
differentiated by genotypes (rs1522813 A-allele carriers and noncarriers and rs2943641T-allele
carriers and noncarriers).
RESULTSdAmongrs1522813A-allelecarriers,thereversionratesoftheMetSwerehigherinthe
high-fat diet group than those in the low-fat diet group over the 2-year intervention (P =0 . 0 0 2 ) ,
whilenosigniﬁcantdifferencebetweendietgroupswasobservedamongnoncarriers(P=0.27 ).The
geneticmodulationondietaryeffectwasindependentofweightchanges.Theoddsratio(OR)forthe
2-year reversionoftheMetSwas2.88(95%CI1.25–6.67)comparingthehigh-fatandlow-fatdiets
among rs1522813 A-allele carriers, while the corresponding OR was 0.83 (0.36–1.92) in noncar-
riers. The variant rs2943641 was not observed to modulate dietary effects on the MetS status.
CONCLUSIONSdOur datasuggestthathigh-fatweight-lossdiets mightbemoreeffectivein
the management of the MetS compared with low-fat diets among individuals with the A-allele of
the rs1522813 variant near IRS1.
Diabetes Care 36:3442–3447, 2013
T
he metabolic syndrome (MetS) is a
constellation of metabolic abnor-
malities including abdominal obe-
sity, dyslipidemia (low HDL cholesterol
levels, and hypertriglyceridemia), ele-
vated blood pressure, and hyperglycemia
(1). It has been well-documented that
the MetS increases the risk of diabetes,
cardiovasculardisease,andall-causemor-
tality (2). Several clinical trials have sug-
gested that dietary intervention is an
effective way to manage the MetS (3–9),
though a speciﬁc therapeutic diet for the
MetS remains to be determined. We have
previously shown that weight-loss diets
varying in macronutrient components
had similar effectiveness in reducing the
prevalenceoftheMetSina2-yearrandom-
ized clinical trial, the Preventing Over-
weight Using Novel Dietary Strategies
(POUNDS LOST) trial (10).
Genetic factorsmay play an important
roleinthedevelopmentoftheMetS.Insulin
receptorsubstrate1(IRS1),encodedbythe
IRS1gene,playsakeyroleintheinsulinsig-
naling pathway (11–13). Recent genome-
wide association studies have identiﬁed
common genetic variants near the IRS1
gene associated with multiple features of
the MetS, such as insulin resistance, ab-
dominal obesity, and dyslipidemia, as
well as risk of diabetes and coronary heart
disease (14–17). Moreover, our previous
gene–diet interaction analysis has shown
that the genetic variant rs2943641 near
IRS1 might modulate the effect of diets
varying in fat content on weight loss and
the improvement of insulin resistance
(18). Thus, we hypothesized that genetic
variation near IRS1 may also modify the
effect of weight-loss diets varying in fat
content on the MetS status.
In the current study, we genotyped
another genetic variant, rs1522813, for
which occurrence is independent of the
previously investigated genetic variant
rs2943641 (r
2 , 0.01) and is also near
IRS1, and compared the effects of the high-
fat and low-fat diets on the reversion of the
MetSaccordingto genotypes of the two var-
iants over a 2-year intervention in 738 over-
weight or obese adults from the POUNDS
LOST trial.
RESEARCH DESIGN AND
METHODS
Study participants
T h eP O U N D SL O S Tt r i a li sa2 - y e a r
randomized clinical trial to compare the
effects of energy-reduced diets with dif-
ferent compositions of fat, protein, and
carbohydrate on weight change. The
study design and methods have been
described in detail elsewhere (10). A total
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ORIGINAL ARTICLEof 811 overweight or obese subjects were
randomly assigned to one of four diets for
2years.Participantshadtobe30–70years
of age and have a BMI of 25–40 kg/m
2.
The target percentages of energy derived
from fat, protein, and carbohydrate in
the four diets were 20, 15, and 65%; 20,
25,and55%;40,15,and45%;and40,25,
and 35%, respectively. Each participant’s
caloric prescription represented a deﬁcit
of 750 kcal/day from baseline, as calcu-
lated from the person’s resting energy
expenditure and activity level. As part of
a two-by-two factorial design, two diets
were low fat (20%) and two were high
fat (40%) and two were average protein
(15%) and two were high protein (25%).
Major criteria for exclusion were the pres-
enceofdiabetesorunstablecardiovascular
disease, the use of medications that affect
body weight, and insufﬁcient motivation.
In the current analysis, 738 subjects with
genotype data were included (91% of the
total subjects in the POUNDS LOST trial).
Among them, 61% were women, 80%
were white, 15% were African American,
3% were Hispanic, and 2% were Asian or
other ethnic groups by self-report. The
study was approved by the human sub-
jects committee at the Harvard School of
Public Health and Brigham and Women’s
Hospital,Boston,MA,andthePennington
Biomedical Research Center of the Louisi-
ana State University System, Baton Rouge,
LA, and by a data and safety monitoring
board appointed by the National Heart,
Lung, and Blood Institute. All participants
gave written informed consent.
Measurements
Body weight and waist circumference
were measured in the morning before
breakfast at baseline, 6 months, and 2
years. Height was measured at baseline.
BMIwascalculatedasweight(kg)/height
2
(m
2). Fasting blood samples were col-
lected at baseline, 6 months, and 2 years,
and serum glucose, insulin, HDL choles-
terol, and triglycerides were measured at
the clinical laboratory at the Pennington
Biomedical Research Center. Insulin re-
sistance was estimated by homeostasis
model assessment of insulin resistance
calculated by the following equation:
(fasting insulin [mU/mL] 3 fasting glu-
cose [mg/dL]/18.01)/22.5 (19). Blood
pressure was measured at baseline, 6
months, and 2 years with the use of
an automated device (HEM-907XL;
Omron). To assess the dietary adherence
across the intervention, dietary intake
was assessed in a random sample of
50% of the participants by a review of
the 5-day diet record at baseline and by
24-h recall during a telephone interview
on 3 nonconsecutive days at 6 months
and 2 years. In addition, food frequency
questionnaires were collected in all partic-
ipants at baseline, 6 months, and 2 years.
Participants’ physical activity levels were
assessedusing the Baecke physicalactivity
questionnaire (20) at baseline, 6 months,
and 2 years.
Genotyping
DNA was extracted from the buffy coat
fraction of centrifuged blood using the
QIAmp Blood Kit (Qiagen, Chatsworth,
CA). Single nucleotide polymorphisms
(SNPs) were genotyped using the Open-
ArraySNPGenotypingSystem(BioTrove,
Woburn, MA). Replicate quality control
samples (10%) were included and geno-
typed with .99% concordance. In addi-
tion to the previously reported SNP,
rs2943641 (18), we genotyped another
SNP, rs1522813, which showed stronger
association with type 2 diabetes than the
SNP rs2943641 in our previous analysis
(21). The allele frequencies of both SNPs in
all participants or in white participants were
in Hardy-Weinberg equilibrium (P.0.05).
Deﬁnition of the MetS
The MetS was deﬁned based on the
National Cholesterol Education Program
Adult Treatment Panel III criteria as pre-
senting at least three of the following
components: 1) abdominal obesity: waist
circumferences $102 cm in men or $88
cm in women; 2) hyperglyceridemia: tri-
glycerides $1.7 mmol/L (150 mg/dL); 3)
low HDL cholesterol levels: HDL choles-
terol ,1.03 mmol/L (40 mg/dL) in men
or ,1.29 mmol/L (50 mg/dL) in women;
4) high blood pressure: blood pressure
$130/85mmHgorcurrentuse ofantihy-
pertensive medications; or 5)h y p e r g l y c e -
mia:fastingplasmaglucose$6.1 mmol/L
(110 mg/dL) (1). Participants who met
t h ec r i t e r i af o rM e t Sa tb a s e l i n eb u tn o t
at the 6-month or 2-year assessment
were deﬁned as the MetS reversion, while
participants who did not meet criteria for
MetSatbaselinebutmetthe criteria at the
6-month or 2-year assessment were de-
ﬁned as the MetS incidence.
Statistical analysis
General linear models for continuous
variables and x
2 test for categorical varia-
bles were applied for the comparison ac-
cording to genotype groups at baseline.
We compared the prevalence of the
MetS and changes in the MetS status (re-
version rate and incidence rate) between
low-fat and high-fat diet groups by geno-
type groups at 6 months and 2 years using
the x
2 test. We used logistic regression
models to calculate the odds ratios (ORs;
[95%CI])ofthereversionsoftheMetSand
individual components by comparing the
high-fat diets with the low-fat diets strati-
ﬁed by genotype groups, adjusted for age,
sex,ethnicity,andchangesinbodyweight.
Gene–diet intervention interactions were
tested by including the genotype-by-diet
interaction terms in the models. We also
used mixed models to test the dietary ef-
fectsonthereversionoftheMetSaccording
to genotype groups over the 2-year inter-
vention. As a result of the relatively small
numbersofminorhomozygotes,hetero-
zygote and minor homozygotes were
combined in the analyses. Because the
majority of the participants were white
(80%), similar analyses were repeated in
white participants. All reported P values
arenominalandtwo-sided,andaPvalue
of 0.05 was considered statistically signiﬁ-
cant. Statistical analyses were performed
with SAS version 9.1 (SAS Institute, Inc.,
Cary, NC).
RESULTSdTable 1 shows the baseline
characteristics of participants according
to the SNP rs1522813 genotype. The ge-
notype frequencies were similar between
men and women, among ethnic groups,
and across the diet groups (all P $ 0.16).
Theprevalenceofelevatedbloodpressure
decreasedacrossthegenotypegroups(P=
0.02), but there was no signiﬁcant differ-
ences in the prevalence of the MetS or
other individual components of the
MetS among the rs1522813 genotype
groups (all P $ 0.12). The other SNP,
rs2943641, showed weak linkage dis-
equilibrium with the SNP rs1522813
(r2 = 0.004, 0.007, and 0.007; D9 =
0.122, 0.244, and 0.475, respectively, in
the HapMap Centre d’Etude du Polymor-
phisme Humain from Utah [CEU],
Yoruba from Ibadan [YRI], and Japanese
population from Tokyo [JPT] + Han Chi-
nese from Beijing [CHB] database [http://
hapmap.ncbi.nlm.nih.gov/], respec-
tively). The baseline characteristics of par-
ticipants according to the SNP rs2943641
genotype have been previously reported
(18). No signiﬁcant differences in the
prevalence of the MetS or individual com-
ponents across the genotype groups were
observed (data not shown).
After dietary intervention, the overall
prevalence of the MetS was reduced from
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Qi and Associates46.0% at baseline to 33.1% at 6 months
and 32.5% at 2 years, and the low-fat and
high-fatdietshadsimilareffectsonchanges
inthe MetSstatus (allP . 0.22).The prev-
alenceoftheMetSwasreducedby11.6and
14.2% at 6 months and 13.1 and 14.0% at
2 years in the low-fat and high-fat diet
groups, respectively.
Table2showstheeffectoflow-fatand
high-fat diets on changes in the MetS sta-
tus stratiﬁed by the rs1522813 GG and
GA/AA genotype groups. Among partici-
pants with GA/AA genotype, the MetS re-
version rate (the proportion of participants
whohadtheMetSbutrevertedat6months
or2years)tendedtobehigherinthehigh-
fat diet group than in the low-fat diet
group at 6 months (42.7 vs. 27.8%; P =
0.06) and at 2 years (45.9 vs. 28.1%; P =
0.04). Among participants with GG geno-
type,thelow-fatandhigh-fatdietsshowed
similar effects on the MetS status at 6
months and 2 years (all P . 0.37). Results
were similar when the analyses were re-
stricted in white participants.
In stratiﬁed analysis by the SNP
rs2943641, we did not observe any sig-
niﬁcant dietary effects on the MetS status
at6monthsor2yearsamongparticipants
with CC genotype or among participants
with CT/TT genotype (all P . 0.28).
Logistic regression analysis conﬁrmed
that high-fat diets were associated with the
reversion of the MetS among participants
with the rs1522813 A-allele (GA/AA geno-
types) (Fig. 1). After adjustment for age,
sex, ethnicity, and body weight changes,
the ORs (95% CI) for the 6-month MetS
reversion for the high-fat diet group com-
pared with low-fat diet group were 2.31
(1.12–4.78) and 0.80 (0.39–1.63) among
participants with and without the
rs1522813 A-allele, respectively (P for
diet–genotype interaction = 0.04). After
further adjustment for physical activity,
the results remained signiﬁcant. Further
adjustment for changes in insulin resis-
tance, estimated by homeostasis model as-
sessment of insulin resistance, did not
changetheresults.Theresultsweresimilar
at2years(ORs[95%CI]2.88[1.25–6.67]
and 0.83 [0.36–1.92], respectively; P for
diet–genotype interaction = 0.04). In our
sensitivity analysis, the criterion for waist
circumference was excluded in the deﬁni-
tion of the MetS. We observed a similar
genotype–diet interaction pattern on the
reversion of the MetS at 6 months and 2
years (P for interaction = 0.12 and 0.002,
respectively).
We then used mixed models to ex-
amine the dietary effects on the reversion
of the MetS over the 2-year intervention
(Fig. 2). Among participants with GA/AA
genotype, the MetS reversion rate was
higher in the high-fat diet group than
that in the low-fat diet group (P =
0.002), while the low-fat and high-fat di-
ets showed similar effects on reversion of
the MetS (P = 0.27) among partici-
pants with GG genotype over the 2-year
intervention.
We ﬁnally examined the dietary ef-
fects on reversion of the components of
the MetS by the SNP rs1522813 geno-
type. Among participants with the
rs1522813 GA/AA genotype, the high-
fat diets showed directionally consistent
effects on reversions of the MetS compo-
nents compared with the low-fat diets,
but the results did not reach a statistically
signiﬁcant level (all P . 0.05) (Supple-
mentary Table 1). We observed marginal
diet–genotype interactions on the rever-
sion of high blood pressure at 6 months
(P for interaction = 0.07) and the rever-
sion of hypertriglyceridemia at 2 years
(P for interaction = 0.08).
CONCLUSIONSdIn this 2-year
weight-loss trial, we examined the
effects of variants near the IRS1 gene on
changes in the MetS status in response to
Table 1dBaseline characteristics of the study participants
All (n =7 3 8 )
rs1522813 genotype
GG (n =3 8 6 ) G A( n =3 0 2 ) A A( n =5 0 ) P value*
Age (years) 51 6 95 1 6 95 1 6 95 0 6 10 0.23
Sex [n (%)] 0.21
Female 450 (61.0) 236 (61.1) 178 (58.9) 36 (72.0)
Male 288 (39.0) 150 (38.9) 124 (41.1) 14 (28.0)
Race or ethnic group [n (%)] 0.42
White 590 (80.0) 318 (82.4) 235 (77.8) 37 (74.0)
Black 112 (15.2) 51 (13.2) 52 (17.2) 9 (18.0)
Hispanic 25 (3.4) 11 (2.8) 12 (4.0) 2 (4.0)
Asian or other 11 (1.5) 6 (1.6) 3 (1.0) 2 (4.0)
Diet groups [n (%)] 0.16
Low-fat diets (20% of calories) 368 (49.9) 187 (48.4) 161 (53.3) 20 (40.0)
High-fat diets (40% of calories) 370 (50.1) 199 (51.6) 141 (46.7) 30 (60.0)
Weight (kg) 93 6 16 93 6 14 94 6 16 91 6 17 0.74
BMI (kg/m
2) 32.7 6 3.9 32.6 6 3.8 32.8 6 4.0 32.4 6 3.9 0.76
Baecke physical activity score 1.58 6 0.11 1.58 6 0.11 1.58 6 0.11 1.59 6 0.12 0.62
MetS [n (%)] 342 (46.3) 185 (47.9) 137 (45.4) 20 (40.0) 0.52
MetS components [n (%)]
Abdominal obesity 598 (81.0) 314 (81.4) 243 (80.5) 41 (82.0) 0.94
Low HDL cholesterol level 413 (56.0) 203 (52.6) 178 (58.9) 32 (64.0) 0.12
Hypertriglyceridemia 341 (46.2) 183 (47.4) 139 (46.0) 19 (38.0) 0.45
Hyperglycemia 47 (6.4) 24 (6.2) 20 (6.6) 3 (6.0) 0.97
High blood pressure 336 (45.5) 193 (50.0) 126 (41.7) 17 (34.0) 0.02
*P values were calculated by x
2 test for categorical variables and general linear models for continuous variables.
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IRS1 genotype modulates MetS reversionweight-loss diets with two different pre-
scribed levels of fat content. We found a
potential interaction between the genetic
variant rs1522813 and diet intervention
on reversion of the MetS at 6 months
and 2 years. Among individuals with the
rs1522813 A-allele, the high-fat diets
showed greater effect on reversion of the
MetScomparedwiththelow-fatdietsover
the 2-year intervention.
Althoughalargebodyofevidencehas
shown that dietary interventions are ben-
eﬁcialinthemanagementoftheMetS,the
ideal dietary intervention remains con-
troversial (3–9). In our previous analysis
of the POUNDS LOST trial, weight-loss
diets with different macronutrient com-
ponents had similar effectiveness in
improving the MetS (10). Our recent gene–
diet interaction analyses in the POUNDS
LOST trial have suggested that the effects
of the diet intervention on body weight
andrelatedmetabolictraitsmightbeinﬂu-
enced by genetic background (18,22–26).
In the current study, our data indicated
that high-fat diets were superior to the
low-fat diets for reversion of the MetS
among individuals with the A-allele of
the rs1522813 variant near IRS1. The ob-
servedgenotype–dietinteractiononrever-
sion of the MetS might be independent
of weight loss or changes in insulin
resistance. This is consistent with the
results that we did not ﬁnd signiﬁcant
genotype–diet interaction on weight loss
or changes in insulin resistance. More-
over, the results were similar when we
excluded the criterion for waist circumfer-
ence in the deﬁnition of the MetS, further
suggesting that the genotype–diet interac-
tiononreversionoftheMetSmightbeless
inﬂuenced by changes in adiposity. Un-
like the weight regain after 6 months, the
dietaryeffectinreducingtheprevalenceof
the MetS persisted at 2 years in the
POUNDS LOST trial (10). This may also
explain the consistent results at 6 months
and 2 years regardless of weight changes
during the intervention. Therefore, these
results indicate a stable and long-term
modiﬁcation effect of the genetic variant
r s 1 5 2 2 8 1 3o nt h eM e t Sr e v e r s i o ni nr e -
sponse to diet interventions. Our data
mayprovideusefulinformationforthede-
velopment of dietary interventions in the
management of the MetS based on genetic
background.
Another genetic variant near IRS1,
rs2943641, which has been previously
shown to interact with dietary fat intake
on the changes in body weight and insulin
resistance (18), did not modulate the die-
taryeffectsontheMetSstatusinthecurrent
analysis. However, it should be noted that
the currently observed interaction between
the genetic variant rs1522813 and diet in-
tervention on reversion of the MetS was in-
dependent of changes in body weight and
insulin resistance. We did not ﬁnd any dif-
ferent dietary effects on weight loss accord-
ing to the rs1522813 genotype (data not
shown). The SNPs rs2943641 and
rs1522813 fall into two independent
linkage disequilibrium blocks with low
correlation (r
2 , 0.01 for all ethnic
groups in the HapMap database) and
showed independent associations with
risk of type 2 diabetes (21). In addition,
therewasaninteractionbetweenphysical
activity and the SNP rs1522813, but not
the SNP rs2943641, on type 2 diabetes
risk in women (21). However, the SNPs
in the same linkage disequilibrium block
with the rs2943641 appear to show stron-
ger associations with various metabolic
traits than the other SNPs near IRS1 (14).
Thus,ourﬁndingstogetherwithotherpre-
viousresultssuggestedthatdifferentmech-
anisms might underlie the observed
associations and interactions for these two
genetic variants. It is possible that the
genetic variant rs2943641 might be more
relatedtoweightlossandinsulinresistance
in response to dietary intervention, while
the genetic variant rs1522813 is more
likely to interact with dietary intervention
onchangesinbloodpressure,plasmaHDL
cholesterol,andtriglycerides.However,the
biologicalfunctionofthesegeneticvariants
has not been clariﬁed, and experimental
studies are needed in the future.
We did not ﬁnd signiﬁcant gene–diet
interactions or dietary effects on the re-
versions of the individual components
of the MetS, but the high-fat diet showed
directionally consistent improvement on
reversions of the MetS components com-
pared with the low-fat diets among par-
ticipants with the rs1522813 A-allele.
These results suggested that the dietary
effect on reversion of the MetS might re-
ﬂect the cumulative effects on the indi-
vidual components rather than on any
single component. This is in line with
the fact that genetic variants near IRS1
were associated with multiple features of
the MetS (14–17,21), though the func-
tion of these genetic variants has not
been clariﬁed. Individuals with the
rs1522813 A-allele, which is the risk al-
lele for type 2 diabetes, had a higher re-
version rate of the MetS by choosing a
high-fat diet compared with those with-
out the A-allele. This is consistent with
some previous results that the risk alleles
of the genetic variants were associated
Table 2dMetabolic syndrome status and weight loss between diet groups by rs1522813
genotype at baseline, 6 months, and 2 years
GG GA/AA
Low-fat
diets
High-fat
diets
P
value*
Low-fat
diets
High-fat
diets
P
value*
Baseline
Participants (n) 187 199 181 171
Prevalence [n (%)] 97 (51.9) 88 (44.2) 0.13 76 (42.0) 81 (47.4) 0.31
6m o n t h s
Participants (n) 171 177 158 153
Prevalence [n (%)] 60 (35.1) 58 (32.8) 0.65 57 (36.1) 48 (31.4) 0.38
Reversion [n (%)]† 34 (37.8) 24 (31.2) 0.37 20 (27.8) 32 (42.7) 0.06
Incidence [n (%)]‡ 4 (4.9) 5 (5.0) 0.98 5 (5.8) 5 (6.4) 0.87
Weight loss (kg) 26.7 6 0.4 26.6 6 0.4 0.83 26.9 6 0.5 26.3 6 0.5 0.33
Weight loss (%) 27.3 6 0.4 27.3 6 0.4 0.97 27.3 6 0.5 26.7 6 0.5 0.42
2y e a r s
Participants (n) 142 150 144 124
Prevalence [n (%)] 46 (32.4) 48 (32.0) 0.94 50 (34.7) 41 (33.1) 0.78
Reversion [n (%)]† 29 (40.9) 23 (34.9) 0.47 18 (28.1) 28 (45.9) 0.04
Incidence [n (%)]‡ 4 (5.6) 5 (6.0) 0.93 4 (5.0) 8 (12.7) 0.10
Weight loss (kg) 24.3 6 0.6 24.1 6 0.6 0.77 24.0 6 0.6 23.7 6 0.6 0.70
Weight loss (%) 24.6 6 0.6 24.6 6 0.6 0.98 24.1 6 0.6 23.9 6 0.6 0.87
*P values were calculated by x
2 test for categorical variables and general linear models for continuous var-
iables. †Participants who met the criteria for MetS at baseline but not at the 6-month or 2-year assessment.
‡Participants who did not meet criteria for MetS at baseline but met the criteria at the 6-month or 2-year
assessment.
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Qi and Associateswith greater beneﬁcial effects of diet in-
terventions (18,27). The potential mech-
anisms underlying these ﬁndings remain
to be investigated. In addition, it is difﬁ-
culttodistinguishtheeffectsofdietaryfat
and carbohydrate responsible for the ob-
served interactions because the high-fat
diets have low carbohydrate content.
To the best of our knowledge, this is
the ﬁrst study to date to investigate the
gene–diet interactions on changes in the
MetS status in a large and long-term ran-
domized trial. However, several limita-
tions of our study should be considered.
Not all participants included in the anal-
ysis had MetS at baseline (;50% of the
participantsmetthe criteriaforthe MetS).
Thismayalsolimitourstatisticalpowerof
the analysis for the reversion of the MetS,
and our study may be underpowered to
detect modest effects and interactions. As
expected, our ﬁndings barely reached the
level of statistical signiﬁcance, and repli-
cation of these results is needed in future.
Participants had difﬁculty achieving the
goals for macronutrient intake of their as-
signed group, but mean differences in fat,
carbohydrate, or protein intake among
the diet groups were signiﬁcant (10). Be-
cause of the relatively small numbers of
incident cases of the MetS, we did not
analyze the incidence of the MetS, and it
is unknown whether the gene–diet inter-
actions were similar to the prevention of
the MetS. The participants of our study
were overweight or obese; therefore, fur-
ther studies are warranted to investigate
whether our ﬁn d i n g sa r ea p p l i c a b l ei n
people with normal weight. In addition,
most of the participants were whites
(;80%), and it remains to be determined
whether our ﬁndings could be general-
ized to other ethnic groups.
In conclusion, we found that the
genetic variant rs1522813 near IRS1
might modulate the effects of weight-
loss diets with different fat content on
the MetS status in a 2-year randomized
trial. Participants with the rs1522813
A-allele might have a higher reversion
rate of the MetS by choosing a high-fat
diet compared with a low-fat diet. These
novel ﬁndings provide supportive evi-
dence for the notion of a personalized di-
etary intervention in the management of
the MetS.
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